loading...

BILAG-based Combined Lupus Assessment (BICLA)

Wallace D; Strand V; Furie R; Petri M; Kalunian K; Pike M; Kelley L; Gordon C

ProQolid

Basic description

  • Published in 2011
Authors

Wallace D; Strand V; Furie R; Petri M; Kalunian K; Pike M; Kelley L; Gordon C

Copyright
Instrument in the public domain
Objective
To assess the disease activity in systemic lupus erythematosus (SLE) in clinical trials.
Therapeutic area
  • Skin and Connective Tissue Diseases
  • Immune System Diseases
  • Rare disease (Orphanet definition)
Therapeutic indication

Lupus Erythematosus, Systemic For more information on this rare disease, please consult the following link: Orphanet page

Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Wallace DJ, Strand V, Furie R, et al. Evaluation of Treatment Success in Systemic Lupus Erythematosus Clinical Trials: Development of the British Isles Lupus Assessment Group-based Composite Lupus Assessment Endpoint. Presented at: ACR 2011: Poster 2265 (Abstract)

Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, Kilgallen B, Bongardt S, Barry A, Kelley L, Gordon C. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014 Jan;73(1):183-90 (Full text article)

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us